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Effect of recombinant human erythropoietin on renal function in
humans. To assess the effect of recombinant human erythropoietin
(r-HuEPO) treatment on renal function, the slopes of the regression
lines of the reciprocal of serum creatinine versus time were compared in
26 patients with renal insufficiency (serum creatinine ranged from 2.3 to
11.7 mgldl) followed for a period of 2.7 to 24 months. Ten patients
received r-HuEPO and the anemia was corrected (Group I). Sixteen
patients did not receive r-HuEPO. Ten of them were anemic (Group LI)
and six had normal hematocrits (Group III). All study groups were
matched for age, diagnosis and degree of renal insufficiency. All cohorts
were followed prospectively (Period B, from the first day of the study to
the time of data analysis or dialysis and transplantation); renal function
was also examined retrospectively (Period A, from the first day of the
study to the time of first renal function measurement). Hematocrit was
lowest in Group II control patients, 27%, highest in the Group ILL
control subjects, 43%, and intermediate in Group I EPO-treated pa-
tients, 36%. Serum creatinine uniformly increased in all three groups of
patients. The rate of progression, as measured by the slopes of the
reciprocal of serum creatinine versus time, however, was similar in all
three groups of subjects and during both periods. The mean slopes for
Group I patients before and after r-HuEPO were, respectively. —0.0058
and —0.0054, that of the control cohorts with low and normal hemato-
crit during period B were —0.0063 and —0.0010, respectively. Thus, it
appeared that neither r-HuEPO administration nor a normal hematocrit
accelerated the deterioration of renal function in these patients with
renal insufficiency.
Recombinant human erythropoietin (r-FIuEPO) is effective in
correcting the anemia of dialysis and pre-dialysis patients [1-4].
Such treatment results in an increased work capacity, an
enhanced sense of well-being, a decreased cardiac index and
reduced angina. However, it has been suggested that correction
of anemia may exacerbate hypertension and accelerate the
deterioration of renal function [1, 2, 5]. While exacerbation of
hypertension has been documented in humans receiving r-
HuEPO, the accelerated decline in renal function has been
documented only in the partially nephrectomized rat model [5,
6]. This paper presents data suggesting that neither r-HuEPO
administration nor a higher hematocrit lead to a clinically
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important change in the rate of progression of renal insuffi-
ciency in the pre-dialysis patient population.
Methods
Patient care and selection
Twenty-six patients with moderate and severe renal insuffi-
ciency were selected from the University of Iowa Hospitals'
Renal Clinic for the current prospective controlled cohort
study. They were divided into three groups: Group I consisted
often patients who received recombinant human erythropoietin
(r-HuEPO) and whose anemia was corrected. Group II was
composed of ten patients who were matched for age, sex,
diagnosis and degree of renal insufficiency with the patients
receiving r-HuEPO. They were anemic, but did not receive
r-HuEPO. Group III consisted of six patients with comparable
diagnosis and degree of renal insufficiency, but who had normal
hematocrits. With this method of patient selection and classifi-
cation, a difference detected between Groups I and II would be
attributable to either r-HuEPO itself or the consequence of
EPO-induced rise in hematocrit. Any difference noted between
Groups II and III could be attributed only to the differences in
hematocrit levels.
To avoid the possibility that changes in the rate of progres-
sion of renal insufficiency might be related to the intrinsic
disease rather than the r-HuEPO or the EPO-induced rise in
hematocrit, we adhered to stringent selection criteria. Patients
with rapidly progressive glomerulonephritis, those receiving
immunosuppressive therapy, and those with acute obstructive
uropathy were excluded. Patients with adult polycystic kidney
disease were likewise excluded, as the clinical course of this
disease may be different from those with chronic glomerulone-
phritis, diabetic nephropathy or hypertensive nephrosclerosis,
the three diagnoses found in our study subjects.
Study design
In each individual patient, hematocrit, serum creatinine and
mean arterial blood pressure were compared between two
periods, A and B. Period A covered the interval from the
beginning of this study retrospectively to the time of the first
renal function measurement in each patient. Period B was the
prospective study period. It began from the first day of the
current study to the time of data analysis or when dialysis
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and/or renal transplantation occurred. Diagnosis was made
entirely on clinical data. Diabetic nephropathy was invariably
accompanied by the presence of diabetic retinopathy, periph-
eral vascular disease and, frequently, gastro-enteropathy.
Hypertensive nephrosclerosis was designated in patients whose
predominant clinical picture was long-standing hypertension
with unremarkable urine sediment and minimal proteinuria. A
diagnosis of chronic glomerulonephritis was made in subjects
with long-standing history of proteinuria and abnormal urine
sediment, many with these findings since childhood. Mean
arterial blood pressure (MAP) = systolic BP-diastolic BP/3,
hematocrit and serum creatinine were determined during each
clinic visit. Mean values of hematocrits and blood pressure
readings were obtained for periods A and B.
To assess whether there was any difference in the rate of
progression of renal insufficiency between periods A and B, two
separate linear regression lines plotting the reciprocal of serum
creatinine against time in each period were created for each
individual, and the slopes of the regression lines were com-
pared. Computed regression lines were based on all available
serum creatinine values within the relevant period. The number
of observations per regression line ranged from 5 to 29, To
determine if there was any difference in the rate of renal
deterioration between the EPO-treated patients and the control
cohorts, the slopes of regression lines in Period B were com-
pared among the three study groups.
Group I patients were followed closely in accordance with
the EPO protocols [7]. The doses of r-HuEPO were adjusted to
achieve a hematocrit level of about 35%. Recombinant human
erythropoietin was initially given three times weekly by the
intravenous route and was later switched to once weekly
subcutaneous injections. In Group II and Group III patients,
the frequency of clinic visits and the nature of their laboratory
tests were determined by the attending nephrologist. All sub-
jects were instructed by renal dieticians to limit their dietary
protein intake to 0.8 to 1.0 g/kg body weight per day.
Statistical analysis
The regression lines of the reciprocal of serum creatinine
against time were calculated using the Clinfo system at the
Clinical Research Center. The two slopes generated from each
patient, one from period A and the other, period B, were
compared by the t-test. All other data were analyzed by one
way analysis of variance, and the values between the two
periods and the three patient groups were compared by the
Duncan's test.
Protocol approval
The protocol was approved by the Committee on Human
Research of the University of Iowa College of Medicine.
Results
Table 1 lists the demographic data of the patients, all of whom
were Caucasians, together with the mean blood pressures and
hematocrits during periods A and B. By selection, the three
groups were similar with respect to age, diagnosis and degree of
renal insufficiency. Mean arterial blood pressure, ranging from
102 to 108 mm Hg, was not different among the groups or
between the periods. The amount of anti-hypertensive medica-
tion was also not different in the three groups of study subjects.
MAP
Age mmHg
Subject yr Sex Dx A B A
Hct
%
B
Group I, EPO-treated patients
DLT 62 M DM 111 110
ELK 64 M HBP 106 99
LAR 44 F DM 102 104
JBB 58 M CON 95 99
LJH 65 M CON 113 108
MEH 70 F DM 103 100
JDL 61 M HBP 104 112
LWC 70 M CON 91 95
RJJ 66 M HBP 113 103
WFL 51 M CGN 94 94
Mean 61 103 102
SD 8 8 6
28
31
25
27
29
26
25
28
31
25
28
2
38
36
35
37
36
36
39
32
38
33
36
2
Group II, Control cohorts with anemia
WS 65 M DM 116 104
RV 56 M HBP 116 98
MV 46 F DM 116 112
LL 51 M CON 107 112
SC 69 M CGN 105 107
MK 61 F DM 99 96
LS 58 M HBP 110 110
RC 66 M CON 111 123
JW 68 M HBP 95 95
JO 56 M CON 100 103
Mean 60 108 105
SD 8 8 9
P NS NS NS
32
33
31
46
36
24
30
34
34
36
33
4
<0.05
27
27
29
24
25
23
28
24
32
30
27
3
<0.05
Group III, Control cohorts with normal hematocrit
GB 56 M CON 93 93
LH 66 M CGN 112 112
DM 56 M CGN 105 102
JC 61 M HBP 111 104
OK 52 F HBP 118 130
DA 57 M CON 109 99
Mean 58 108 107
SD 5 8 13
P NS NS NS
49
44
46
56
36
44
46
7
<0.05
48
40
36
50
38
44
43
6
<0.05
ANOVA
DF 2/23 5/46
F 0.339 0.623
P 0.716 0.683
5/46
30.623
<0.0001
All 3 study groups were matched for age, diagnosis and degree of
renal insufficiency, Under the heading of diagnosis (Dx), abbreviations
are: DM, diabetic nephropathy; HBP, hypertensive nephrosclerosis;
and CON, chronic glomerulonephritis. Each patient was studied twice
and designated as periods A and B. The former extended from the first
day of the study retrospectively to when renal function was first
measured, and the latter was the prospective study period which began
from the first day of the study to the time of data analysis or when
dialysis or renal transplantation was instituted. Data are presented as
mean SD and the differences among study groups and between
periods were assessed by one-way analysis of variance and Duncan's
test; degree of freedom (DF), F and P values are listed. The differences
between Groups I and II are listed as P values under Group II data and
that between Groups II and III are listed as P values below Group III
data.
a Significant difference (P < 0.05) between periods A and B.
While mean hematocrit increased from 28 to 36% in Group I or
EPO patients, it decreased from 33 to 27% in the control anemic
cohorts. In Group III patients, mean hematocrit were 46 and
43%, respectively, in periods A and B.
Table 1. Changes in mean arterial blood pressure and hematocrit in
erythropoietin-treated patients as compared to controlled cohorts
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Table 2. Comparison of the slopes of the reciprocals of serum creatinine plotted against time between erythropoietin-treated patients and
controlled cohorts
Serum Cr mg/dl
—_Observation months
1/Serum Cr
Slope R value
A B
A B
Subjects I F I F A B A B
Group I, EPO-treated patients
DLT 1.7 3.6 3.6 3.5 47.6 (11) 23.8 (29) —0.007 —0.005 —0.83 —0.76
ELK 4.3 6.8 6.8 8.2+ 46.3 (23) 9.9 (20) —0.001 —0.005 —0.80 —0.47
LAR 3.2 6.1 6.1 6.4+ 12.0 (9) 9.2 (16) —0.017 —0.74 —0.44
JBB 6.1 10.2 10.2 11.8+ 24.9 (II) 5.9 (17) —0.003 —0.006 —0.95 —0.22
LJH 3.3 7.6 7.6 16.3+ 16.2 (7) 4.4 (14) —0.006 —0.018 —0.72 —0.98
MEH 8.1 6.2 6.2 6.7+ 12.6 (IS) 16.9 (24) 0.003 —0.0003 0.26 —0.12
JDL 5.6 11.7 11.7 14.2+ 10.5 (27) 2.8 (10) —0.005 —0.012 —0.63 —0.88
LWC 4.6 6.5 6.5 8.8+ 8.5 (5) 17.4 (23) —0.006 —0.004 —0.92 —0.90
RJJ 3.7 4.3 4.5 3.1 4.0 (9) 10.0 (14) —0.010 0006b —0.68 0.84
WFL 3.7 3.2 3.2 4.4 18.1 (16) 17.2 (21) —0.005 —0.006 —0.43 —0.50
Mean 4.4 6.6a 6.6 8.3 20.1 11.8 —0.0058 —0.0054 0.71 0.59
sD 1.8 2.7 2.7 4.5 15.2 6.8 0.0052 0.0064 0.23 0.29
Group II, Control cohorts with anemia
WS 3.8 6.1 6.1 7.9+ 31.6 (17) 20.4 (16) —0.003 —0.002 —0.94 0.94
RV 3.4 6.3 6.3 11.9+ 43.7 (Il) 12.6 (12) —0.003 —0.007 —0.86 —0.94
MV 3.8 5.8 5.8 8.4+ 5.6 (6) 9.3 (22) —0.009 0.0007 —0.09 0.09
LL 1.1 2.3 2.3 19.5+ 30.7 (8) 29.8 (5) —0.016 —0.013 —0.55 —0.99
SC 6.9 8.1 8.1 18.8+ 26.4 (13) 5.8 (9) —0.001 —0.011 —0.54 —0.97
MK 2.3 6.8 6.8 7.6+ 18.9 (26) 2.7 (8) —0.016 —0.007 —0.96 —0.30
LS 3.8 5.5 5.5 9.3+ 25.0 (21) 8.6 (8) —0.002 —0.009 —0.40 —0.96
RC 3.7 6.0 6.0 10.9+ 18.7 (8) 8.9 (8) —0.007 —0.008 —0.89 —0.92
JW 6.3 5.0 5.0 7.1+ 13.0 (10) 8.6 (9) 0.00004 —0.003 —0.01 —0.51
JG 3.8 4.6 4.6 12.0+ 15.6 (6) 12.2 (8) —0.0001 —0.005 0.06 —0.88
Mean 3.9 5.6 5.6 ll.3a 22.9 11.9 —0.0055 —0.0063 0.56 0.73
sD 1.7 1.5 1.5 4.5 10.9 7.8 0.0060 0.0041 0.36 0.32
P NS NS NS NS NS NS NS NS NS NS
Group III, Control cohorts with normal hematocrit
GB 4.7 5.5 5.5 6.4 9.1 (6) 19.1 (6) —0.003 —0.0002 —0.43 —0.09
LH 4.5 5.1 5.1 9.9 3.3 (5) 19.1 (II) —0.002 0.0005 —0.27 0.30
DM 2.2 2.9 2.9 6.0 39.3 (9) 24.0 (6) —0.003 —0.008 —0.73 —0.98
JC 6.2 6.5 6.5 6.0+ 25.8 (9) 14.3 (6) —0.002 —0.007 —0.70 —0.99
OK 4.3 5.0 5.5 5.0+ + 9.7 (8) 15.4(11) —0.004 —0.001 —0.66 —0.27
DA 2.5 7.6 7.6 5.2++ 56.0 (7) 6.0 (6) —0.004 0.01 —0.96 0.84
Mean 4.1 5.5 5.5 6.4 23.9 16.3 —0.0029 —0.0009 0.63 0.58
SD 1.5 1.6 1.6 1.8 20.6 6.1 0.0011 0.0063 0.25 0.40
P NS NS NS <0.05 NS NS NS NS NS NS
DF 5/46 5/46 5/46 5/46 5/46
F 2.870 4.372 1.797 1.096 0.529
P 0.025 0.002 0.132 0.376 0.753
See footnote of Table I for explanation of study periods A and B. Under each period, I and F refer to the values obtained, respectively, at the
beginning and the end of each period. (+) and (+ +) indicate those who had undergone, respectively, dialysis and renal transplantation. Slopes were
derived from the linear regression lines plotting the reciprocal of serum creatinine against time. The number of observations or (N) that entered
into the calculation of slopes and R values are indicated by the number inside each parenthesis under the column "Observation." One-way analysis
of variance and Duncan's test were used to assess the significance of the differences among study groups and between periods. The results as listed
as degree of freedom (DF), F and P values. The differences between Groups I and 11 are listed under Group II data, and the differences between
Groups II and III are listed under Group III data.
a Significant differences between initial and final values during each period.b Pvalue of <0.01. The differences between slooes A and B for individual subjects were tested by t-test using equations listed below:
t = S — S2/\/MSE,[l/(n — l)(SD1X1) + l/(n, — l)(SD2X,)]MSEp = (n1 — 2)MSEI + (n2 — 2)MSE2/n1 + n2 — 4
MSEp = pooled mean square error
MSE1 = square error of regression line #1
MSE2 = square error of regression line #2
SDIXI = standard deviation of months of observation for period A
SD2X2 = standard deviation of months of observation for period B
Degree of freedom = n1 + n2 — 4
Table 2 and Figure 1 compare the progression of renal who had normal hematocrit (Group III). Serum creatinine
insufficiency between EPO-treated patients (Group I) and the increased in all groups, but the increment was greatest in Group
matched control cohorts who were either anemic (Group II) or II subjects, those who did not receive r-HuEPO and remained
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Fig. 1. Regression lines plotting the reciprocal of serum creatinine versus time in erythropoietin-treated patients (A), control cohorts who did not
receive erythropoietin and were anemic (B), and control cohorts who did not receive e,ythropoietin but had normal hematocrit (C). Each line
depicts one subject. There were 10 subjects included in A, 10 in B and 6, C. The number of observations that entered into the calculation for the
slopes are listed in Table 2. The heavy line connecting the solid squares in each panel represents the mean slope of the regression lines for each
group. The 0 month point denotes the separation of Periods A and B; to the left is the retrospective, and to the right is the prospective study period.
Mean slopes of the two periods for the erythropoietin-treated group were —0.0058 and —0.0054, for the control cohorts with anemia were —0.0055
and —0.0063, for the control subjects with normal hematocrit were —0.0029 and —0.0010. None of the slopes were statistically different from one
another.
anemic. The duration of observation for period B (the prospec-
tive study period), which ranged from 4.4 to 23.9 months, was
not different among the three study groups. Comparison of the
slopes of the linear regression plots of the reciprocal of serum
creatinine versus time obtained from each individual subject
failed to detect any difference between the two periods, with the
exception of LAR and RJJ of the EPO-treated group. In these
two patients, the rate of decline of renal function appeared to be
slower in the EPO-treatment period. More importantly, as
shown in Table 2, the mean slopes for Group I were not
different between the two observation periods (—0.0058 vs.
—0.0054), that is, before and after initiation of r-HuEPO.
Furthermore, matched cohort subjects who had not received
r-HuEPO had comparable slopes of reciprocal of serum creat-
mine against time as the EPO group whether they were anemic
(Group II, —0.0063) or had normal hematocrit (Group III,
—0.0010). To provide the readers an idea of how well the
individual serum creatinine levels fit into the slopes, R values
for individual regression lines are listed in Table 2. No differ-
ences were noted among the groups and between the study
periods. In calculating the mean R value for each group, we
have taken only the absolute values and ignored the polarity
because we are only interested in the degree of tightness of the
fit and not the directional change.
Discussion
The concern that r-HuEPO might induce a more rapid dete-
rioration of renal function in patients whose serum creatinine is
already elevated is derived from theoretical consideration and
from data generated in the partially nephrectomized uremic rat
model. In normal rats, a reduction of hematocrit results in an
acute rise in renal blood flow and single nephron glomerular
filtration rate. Since the rise in renal blood flow is greater than
the increase in glomerular filtration rate, filtration fraction
decreases. Simultaneously, there is a reduction in afferent and
efferent glomerular arteriolar resistance, resulting in a reduced
glomerular transcapillary pressure. A rise in hematocrit re-
verses these changes and results in an increased transcapillary
pressure within the glomerulus [8, 91. Thus, Garcia and col-
leagues studied three groups of 5/6 nephrectomized Wistar rats.
One group served as the controls, a second was made anemic
by a combination of iron deficient diet and periodic phlebot-
omy, and a third received recombinant human erythropoietin.
Both hematocrit and glomerular transcapillary pressure were
highest in the EPO-treated group and lowest in the group with
iron-deficiency anemia. Moreover, the degree of glomerulo-
sclerosis was correlated in a direct fashion with the hematocrit
[5]. Similarly, Gretz et al found that erythropoietin-treated 5/6
nephrectomized rats were less anemic, but had a higher mor-
tality rate than the control nephrectomized rats. Five of the 12
EPO-treated rats died before the end of the study, three
succumbing to acute renal failure. By contrast, none of the
control rats died [6].
Fortunately, the safety record of recombinant human eryth-
ropoietin is better in man. During the Ortho Pharmaceutical-
sponsored study, none of 117 pre-dialysis patients given r-
HuEPO developed acute worsening of renal function [10]. We
have reported that there is no significant change in renal
function following eight weeks of erythropoietin treatment [3].
In the current study, pre-dialysis patients treated with r-HuEPO
for a mean duration of 11.8 months (range 4 to 24 months) did
not show a more rapid rate of decline in renal function than
before r-HuEPO treatment or in comparison with non-EPO
treated controls. This conclusion was based upon analysis of
A Erythropoietin
treated
—60 —40 —20 0 20 —40 —20 0 20 —40 —20 0 20
Time, months
Lim et a!: r-HuEPO and renal function in humans 135
the slopes of the reciprocal of serum creatinine versus time and
comparison of the slopes derived from the same subjects before
and after erythropoietin therapy (Table 2 and Fig. 1). During
short-term study, other groups of investigators have also re-
ported that r-HuEPO does not have a deleterious effect on renal
function in man [11—131.
The difference between rat and human data may, in part, be
due to better control of blood pressure in our patients. Alter-
natively, the absence of adverse effects on renal function in man
may be attributable to the smaller increment in hematocrit
levels which ranged from 27 to 43%. By contrast, hematocrits
ranged from 27 to 51% between anemic and EPO-treated rats.
Since Mitch et al introduced the use of reciprocal serum
creatinine plots to assess the progression of renal insufficiency
[14], this technique has been widely used to assess the effect of
diet and medication on renal function [15—18]. Although the
correlation coefficient (r value) of such plots is generally quite
high, the issue as to whether this method accurately reflects
changes in glomerular filtration has not been rigorously tested.
Many investigators, including those of the Modification of Diet
in Renal Disease (MDRD) Study, who are evaluating the effect
of low protein diet find that the slope of reciprocal serum
creatinine plots underestimates the decline in glomerular filtra-
tion rate as measured by isotopic or inulin clearances [19—22].
This type of discrepancy may be more unique to patients who
are assigned a low protein diet which reduces meat consump-
tion and may decrease body muscle mass over time. It is
conceivable that such a discrepancy will be less serious in
subjects who are not protein restricted. Creatinine clearance is
not a superior measurement because of the unpredictable effect
of renal impairment on tubular secretion of creatinine [231. We
used the reciprocal serum creatinine versus time plots in the
current study because that was the only quantitative measure-
ment of renal function available for retrospective analysis in our
patients. Furthermore, financial constraint prohibited us from
measuring the isotopic or inulin clearance prospectively. We
reasoned that given sufficient duration of observation and
enough patients, it is unlikely that significant deterioration of
renal function would not be reflected by a declining reciprocal
of serum creatinine. More importantly, dietary protein intake
was quite liberal, in the range of 0.8 to 1.0 g/kglday, in our
patients. This is especially true in the r-HuEPO subjects who
were feeling very well and whose appetite was excellent. It
would be unlikely that their serum creatinine was dispropor-
tionately low because of reduced body muscle mass and de-
creased protein intake during the period of observation.
In summary, the current study demonstrated that neither
erythropoietin treatment nor a normal hematocrit adversely
affect renal function in azotemic pre-dialysis patients. It also
showed that the presence of anemia did not protect against
progressive decline of renal function. Since the duration of this
study ranged only from 4 to 24 months, longer surveillance
should be continued to confirm this lack of toxicity. Further-
more, these conclusions should be considered tentative until
confirmed by more definitive study using a true glomerular
filtration marker.
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